Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$187.39 USD

187.39
518,414

+1.13 (0.61%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $187.54 +0.15 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 245)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.

Zacks Equity Research

Inspire Medical (INSP) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.

Zacks Equity Research

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Zacks Equity Research

CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio

by Zacks Equity Research

CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.

Zacks Equity Research

Zacks.com featured highlights include Universal Health Services, General Motors, Unum and PVH

by Zacks Equity Research

Universal Health Services, General Motors, Unum and PVH have been highlighted in this Screen of The Week article.

Zacks Equity Research

Acadia Healthcare (ACHC) Shares Up 12% on Q2 Earnings Beat

by Zacks Equity Research

Acadia Healthcare's (ACHC) Q2 results reflect higher revenue per patient day and increased patient days. It currently estimates 2024 adjusted EPS within $3.45-$3.65 compared with the earlier view of $3.40-$3.70.

Zacks Equity Research

Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

by Zacks Equity Research

Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.

Zacks Equity Research

Inspire Medical (INSP) Gets FDA Nod for Inspire V System

by Zacks Equity Research

Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.

Sumit Singh headshot

4 Low P/CF Stocks to Turn Market Volatility Into Opportunity

by Sumit Singh

Value investing is essentially about selecting stocks that are cheap but fundamentally sound. UHS, GM, UNM & PVH boast a low P/CF ratio.

Zacks Equity Research

Merit Medical (MMSI) Q2 Earnings & Revenues Beat, '24 View Up

by Zacks Equity Research

Merit Medical's (MMSI) second-quarter results reflect growth in earnings and revenues. Operating margin expands.

Zacks Equity Research

Ecolab (ECL) Sells Surgical Solutions Business to Medline

by Zacks Equity Research

Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.

Zacks Equity Research

Are Investors Undervaluing Universal Health Services (UHS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks.com featured highlights Universal Health Services, Tenet Healthcare Corp., Century Communities and Magnite

by Zacks Equity Research

Universal Health Services, Tenet Healthcare Corp., Century Communities and Magnite are part of the Zacks Screen of the Week article.

Zacks Equity Research

QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down

by Zacks Equity Research

QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.

Zacks Equity Research

CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut

by Zacks Equity Research

CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like UHS, THC, CCS and MGNI that are seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

by Zacks Equity Research

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Zacks Equity Research

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Zacks Equity Research

Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength

by Zacks Equity Research

Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.

Zacks Equity Research

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

Zacks Equity Research

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

by Zacks Equity Research

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

Zacks Equity Research

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.